{"id":36051,"date":"2021-07-01T19:05:01","date_gmt":"2021-07-01T17:05:01","guid":{"rendered":"https:\/\/www.inovallee.com\/?p=36051"},"modified":"2021-07-01T19:05:01","modified_gmt":"2021-07-01T17:05:01","slug":"nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale","status":"publish","type":"post","link":"https:\/\/www.inovallee.com\/en\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/","title":{"rendered":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales"},"content":{"rendered":"<p>C\u2019est une premi\u00e8re pleine de promesses pour les patients atteints de tumeurs c\u00e9r\u00e9brales. Le laboratoire NH TherAguix d\u00e9veloppant le candidat m\u00e9dicament AGuIX combinant trois facteurs d\u00e9terminants pour lutter contre les tumeurs \u00e0 partir d\u2019une seule injection intraveineuse, en partenariat avec le CHU Grenoble Alpes, viennent de publier les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human. Effectu\u00e9 sur 15 patients, celui-ci a permis d\u2019\u00e9valuer les performances de la combinaison d\u2019AGuIX avec la radioth\u00e9rapie, sa faisabilit\u00e9 et surtout sa s\u00e9curit\u00e9 pour les patients. AGuIX cible sp\u00e9cifiquement les m\u00e9tastases c\u00e9r\u00e9brales et est retenu dans les tumeurs jusqu&rsquo;\u00e0 une semaine, permettant une radiosensibilisation pendant le fractionnement du traitement. La dose de 100 mg\/kg, test\u00e9e sans survenue de toxicit\u00e9, a \u00e9t\u00e9 retenue pour l\u2019essai de phase II en cours. Ce nanom\u00e9dicament administr\u00e9 par voie intraveineuse p\u00e9n\u00e8tre dans la tumeur solide et permet, gr\u00e2ce \u00e0 son effet radiosensibilisant, d\u2019amplifier l\u2019efficacit\u00e9 de la radioth\u00e9rapie, tout en ciblant plus pr\u00e9cis\u00e9ment les tissus infect\u00e9s et donc, de r\u00e9duire l\u2019exposition aux radiations des tissus sains limitrophes.<\/p>\n<p>Source\u00a0: communique de presse de <a href=\"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/2021_05_11_NH_TherAguix_CP_publications_nanorad_1_Radiotherapy_Oncology_Vdef.pdf\">NH TherAguix<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>C\u2019est une premi\u00e8re pleine de promesses pour les patients atteints de tumeurs c\u00e9r\u00e9brales. Le laboratoire NH TherAguix d\u00e9veloppant le candidat m\u00e9dicament AGuIX combinant trois facteurs d\u00e9terminants pour lutter contre les tumeurs \u00e0 partir d\u2019une seule injection intraveineuse, en partenariat avec le CHU Grenoble Alpes, viennent de publier les premiers r\u00e9sultats de l\u2019essai clinique phase 1 [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":36052,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28,29],"tags":[157],"class_list":["post-36051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actus-entreprises","category-evenements","tag-nh-theraguix"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e<\/title>\n<meta name=\"description\" content=\"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.inovallee.com\/en\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e\" \/>\n<meta property=\"og:description\" content=\"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.inovallee.com\/en\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/\" \/>\n<meta property=\"og:site_name\" content=\"inovall\u00e9e\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/technopoleinovallee\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T17:05:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1230\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Val\u00e9rie BERTRAND\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@inovallee\" \/>\n<meta name=\"twitter:site\" content=\"@inovallee\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Val\u00e9rie BERTRAND\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/\"},\"author\":{\"name\":\"Val\u00e9rie BERTRAND\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/16ce8129e17b4871a123504e8f87f4ee\"},\"headline\":\"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales\",\"datePublished\":\"2021-07-01T17:05:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/\"},\"wordCount\":239,\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/NH-Theraguix-nanomedecine.jpg\",\"keywords\":[\"NH Theraguix\"],\"articleSection\":[\"Sucess stories des entreprises d'inovall\u00e9e\",\"Technopole inovall\u00e9e\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/\",\"name\":\"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/NH-Theraguix-nanomedecine.jpg\",\"datePublished\":\"2021-07-01T17:05:01+00:00\",\"description\":\"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/NH-Theraguix-nanomedecine.jpg\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/NH-Theraguix-nanomedecine.jpg\",\"width\":1230,\"height\":410,\"caption\":\"NH Theraguix nanom\u00e9dicament\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.inovallee.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"name\":\"inovall\u00e9e technopole, Home to software & smart technologies\",\"description\":\"Home to software &amp; smart technologies\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.inovallee.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\",\"name\":\"inovall\u00e9e\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"width\":945,\"height\":369,\"caption\":\"inovall\u00e9e\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/technopoleinovallee\\\/\",\"https:\\\/\\\/x.com\\\/inovallee\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/inovall-e\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/inovallee?reload=9\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/16ce8129e17b4871a123504e8f87f4ee\",\"name\":\"Val\u00e9rie BERTRAND\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","description":"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.inovallee.com\/en\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/","og_locale":"en_GB","og_type":"article","og_title":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","og_description":"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.","og_url":"https:\/\/www.inovallee.com\/en\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/","og_site_name":"inovall\u00e9e","article_publisher":"https:\/\/www.facebook.com\/technopoleinovallee\/","article_published_time":"2021-07-01T17:05:01+00:00","og_image":[{"width":1230,"height":410,"url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg","type":"image\/jpeg"}],"author":"Val\u00e9rie BERTRAND","twitter_card":"summary_large_image","twitter_creator":"@inovallee","twitter_site":"@inovallee","twitter_misc":{"Written by":"Val\u00e9rie BERTRAND","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#article","isPartOf":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/"},"author":{"name":"Val\u00e9rie BERTRAND","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/16ce8129e17b4871a123504e8f87f4ee"},"headline":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales","datePublished":"2021-07-01T17:05:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/"},"wordCount":239,"publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"image":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg","keywords":["NH Theraguix"],"articleSection":["Sucess stories des entreprises d'inovall\u00e9e","Technopole inovall\u00e9e"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/","url":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/","name":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","isPartOf":{"@id":"https:\/\/www.inovallee.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#primaryimage"},"image":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg","datePublished":"2021-07-01T17:05:01+00:00","description":"Le laboratoire NH TherAguix en partenariat avec le CHU Grenoble Alpes viennent de d\u00e9voiler les premiers r\u00e9sultats du nanom\u00e9dicament AGuIX.","breadcrumb":{"@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#primaryimage","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2021\/06\/NH-Theraguix-nanomedecine.jpg","width":1230,"height":410,"caption":"NH Theraguix nanom\u00e9dicament"},{"@type":"BreadcrumbList","@id":"https:\/\/www.inovallee.com\/nh-theraguix-et-le-chu-grenoble-alpes-publient-les-premiers-resultats-de-lessai-clinique-phase-1-first-in-human-demontrant-les-capacites-de-la-solution-aguix-a-cibler-les-metastases-cerebrale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.inovallee.com\/"},{"@type":"ListItem","position":2,"name":"NH TherAguix et le CHU Grenoble-Alpes publient les premiers r\u00e9sultats de l\u2019essai clinique phase 1 First in Human d\u00e9montrant les capacit\u00e9s de la solution AGuIX \u00e0 cibler les m\u00e9tastases c\u00e9r\u00e9brales"}]},{"@type":"WebSite","@id":"https:\/\/www.inovallee.com\/#website","url":"https:\/\/www.inovallee.com\/","name":"inovall\u00e9e technopole, Home to software & smart technologies","description":"Home to software &amp; smart technologies","publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.inovallee.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.inovallee.com\/#organization","name":"inovall\u00e9e","url":"https:\/\/www.inovallee.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","width":945,"height":369,"caption":"inovall\u00e9e"},"image":{"@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/technopoleinovallee\/","https:\/\/x.com\/inovallee","https:\/\/www.linkedin.com\/company\/inovall-e\/","https:\/\/www.youtube.com\/user\/inovallee?reload=9"]},{"@type":"Person","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/16ce8129e17b4871a123504e8f87f4ee","name":"Val\u00e9rie BERTRAND"}]}},"_links":{"self":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/36051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/comments?post=36051"}],"version-history":[{"count":0,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/36051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media\/36052"}],"wp:attachment":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media?parent=36051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/categories?post=36051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/tags?post=36051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}